NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007

Rena M. Conti, Ernst R. Berndt

NBER Working Paper No. 20016
Issued in March 2014
NBER Program(s):   HC   HE   PR

We examine the impact of loss of U.S. patent exclusivity (LOE) on the prices and utilization of specialty drugs between 2001 and 2007. We limit our empirical cohort to drugs commonly used to treat cancer and base our analyses on nationally representative data from IMS Health. We begin by describing the average number of manufacturers entering specialty drugs following LOE. We observe the number of manufacturers entering the production of newly generic specialty drugs ranges between two and five per molecule in the years following LOE, which is generally less than that observed historically for non-specialty drugs. However, the existence of time-varying and unobservable contract manufacturing practices complicates the definition of “manufacturers” entering this market. We use pooled time series methods to examine whether the neoclassical relationship between price declines and volume increases upon LOE holds among these drugs. First, we examine the extent to which estimated prices of these drug undergoing LOE fall with generic entry. Second, we estimate reduced form random effects models of utilization subsequent to LOE. We observe substantial price erosion after generic entry; average monthly price declines appear to be larger among physician-administered drugs (38-46.4%) compared to oral drugs (25-26%). Additionally, we find average prices for drugs produced by branded manufacturers rise and prices for drugs produced by generic manufacturers fall upon LOE. The latter effect is particularly large among oral drugs. In pooled models, volume appears to increase following generic entry, but this result appears to be largely driven by oral drugs. We discuss second-best welfare consequences of these results.

download in pdf format
   (1306 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

This paper is available as PDF (1306 K) or via email.

This paper was revised on August 8, 2014

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w20016

Users who downloaded this paper also downloaded these:
Hockenberry and Helmchen w20017 The Nature of Surgeon Human Capital Depreciation
Heckman, Humphries, Veramendi, and Urzua w19971 Education, Health and Wages
Helland, Lakdawalla, Malani, and Seabury w20005 Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market
Bunten and Kahn w20018 The Impact of Emerging Climate Risks on Urban Real Estate Price Dynamics
Jones, Reedy, and Weinberg w19866 Age and Scientific Genius
 
Publications
Activities
Meetings
NBER Videos
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us